NCT07671989 Period Pills for Menstrual Regulation: A New Reproductive Health Option
| NCT ID | NCT07671989 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Menstrual Regulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-06-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2026-06-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Period Pills Study is a prospective observational study among people who decide to use a combination of mifepristone and misoprostol for menstrual regulation.
Eligibility Criteria
Inclusion Criteria: * Be 18 years old or older * Read and speak English * Know the date of their last menstrual period within 2 days * Have a period that is late by up to 21 days * Must have had regular periods in the last 4 months * Does not want to be pregnant * Does not want to verify pregnancy status * Understand that if they are pregnant, the pills will end their pregnancy * Does not have contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable) Exclusion Criteria: * Under 18 years old * Does not read and speak English * Does not know the date of their last menstrual period within 2 days * Has not had regular periods in the last 4 months * Wants to be pregnant * Wants to verify pregnancy status * Does not display understanding that if they are pregnant, the pills will end their pregnancy * Has any contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable)
Contact & Investigator
Ushma D Upadhyay, PhD, MPH
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07671989 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Menstrual Regulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07671989 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07671989 currently recruiting?
Yes, NCT07671989 is actively recruiting participants. Contact the research team at ushma.upadhyay@ucsf.edu for enrollment information.
Where is the NCT07671989 trial being conducted?
This trial is being conducted at Oakland, United States, Roanoke, United States.
Who is sponsoring the NCT07671989 clinical trial?
NCT07671989 is sponsored by University of California, San Francisco. The principal investigator is Ushma D Upadhyay, PhD, MPH at University of California, San Francisco. The trial plans to enroll 100 participants.